Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $61.27, for a total value of $490,160.00. Following the sale, the chief financial officer now owns 95,679 shares of the company’s stock, valued at $5,862,252.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, March 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $69.02, for a total value of $552,160.00.

Vaxcyte Trading Up 1.3 %

Vaxcyte stock opened at $61.60 on Tuesday. The stock has a 50 day moving average of $69.09 and a 200-day moving average of $61.21. The stock has a market cap of $6.70 billion, a P/E ratio of -14.92 and a beta of 0.89. Vaxcyte, Inc. has a 52 week low of $41.57 and a 52 week high of $82.04.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same quarter in the previous year, the company posted ($0.73) EPS. As a group, equities analysts predict that Vaxcyte, Inc. will post -4.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxcyte

Large investors have recently modified their holdings of the stock. Mutual of America Capital Management LLC acquired a new stake in Vaxcyte during the fourth quarter valued at approximately $3,035,000. Wellington Management Group LLP increased its holdings in shares of Vaxcyte by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock valued at $234,442,000 after acquiring an additional 167,501 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Vaxcyte by 20.6% in the 3rd quarter. Jennison Associates LLC now owns 1,754,691 shares of the company’s stock worth $89,454,000 after buying an additional 300,189 shares during the last quarter. UBS Group AG lifted its position in shares of Vaxcyte by 62.2% in the 3rd quarter. UBS Group AG now owns 74,305 shares of the company’s stock worth $3,788,000 after buying an additional 28,483 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Vaxcyte by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 8,284,246 shares of the company’s stock valued at $422,331,000 after buying an additional 47,872 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PCVX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a research report on Wednesday, April 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Finally, Bank of America raised their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Four research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $78.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.